Global Research Antibodies and Reagents Market – Industry Trends and Forecast to 2030

Research Antibodies and Reagents Market Analysis and Size

Increased demand for high-quality antibodies for reproducible research will propel the market growth during the forecast period of 2023-2030. The market is also expanding as a result of the expanding landscape of proteomics and genomics research, as well as increased R&D efforts in the life sciences domain. Furthermore, the market is influenced by the rise of industry-academia collaborations and the expanding stem cell research and neurobiology research fields to meet unmet medical needs worldwide.

Data Bridge Market Research analyses that the research antibodies and reagents market which was USD 1178.4 billion in 2022, is expected to reach USD 1921.14 billion by 2030, at a CAGR of 6.3% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Research Antibodies and Reagents Market Scope and Segmentation

Market Definition

Research antibodies and reagents are used to detect an unconjugated primary antibody, which is then used to target antigen. These products aid in the detection, measurement, and purification of proteins or biomolecules in a variety of applications such as flow cytometry, ELISA, western blotting, and immunohistochemistry.

Global Research Antibodies and Reagents Market Dynamics

Drivers

• Increased investment in medical and health R&D

Increased investment in medical and health R&D is expected to contribute to the research antibodies and reagents market growth. Antibodies and reagents are critical components in the investigation of biological processes or disease causes through careful experimentation, observation, laboratory work, analysis, and testing in the field of life science research. According to statistics published by the American Association for the Advancement of Science (AAAS) in December 2019, total investment in medical and health research in the United States increased by 6.4%. The health industry invested $129.5 billion (66.7%), followed by federal agencies' investments of $43 billion (22.2%) and foundations, state and local governments, academic research institutions, and voluntary health associations' investments of $21.7 billion (11.2%). Thus, rising investment in healthcare research and development sector will increase the utilization of research antibodies and reagents.

• Increasing prevalence of neurodegenerative diseases

Antibodies are now one of the most important tools for research projects investigating the functions of various proteins in cells. The increasing prevalence of neurodegenerative diseases such as Huntington's disease, Multiple Sclerosis, and Parkinson's disease is fuelling research opportunities aimed at better understanding these diseases. Furthermore, the growing geriatric population and a scarcity of chronic disease treatments have contributed to a surge in demand for research antibodies to develop personalized medicines, cutting-edge pharmaceuticals, and novel and effective treatments.

Opportunities

• Technological advancements in the purification of antibodies

Technological advancements in the purification of antibodies and reagents indicate opportunities for the growth of the research antibodies and reagents market during the forecast period. In 2019, Genscript announced the launch of AmMag technology, a semi-automatic purification instrument that reduces the purification process from days to hours. The AmMag SA was created under a license agreement with Amgen.

Restraints/Challenges

• High cost

The cost and time-intensive antibody development processes, as well as pricing pressure on prominent players, are expected to hamper the growth of the research antibodies and reagents market. The research antibodies and reagents market is expected to face challenges from rising quality concerns and a lack of reproducible results during the forecast period.

This research antibodies and reagents market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the research antibodies and reagents market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on the Research Antibodies and Reagents Market

The increasing number of COVID-19 cases has significantly increased research-based activities aimed at developing effective diagnosis or therapy. The increasing number of research activities is driving end-user adoption of research antibodies and reagents. Manufacturers and organizations have launched the following initiatives: The Canadian government committed USD 205.5 million for coronavirus research in March 2020, increasing global funding. This investment will be used to conduct research on medical countermeasures to COVID-19. European governments have pledged over USD 7.67 billion (EUR 7 billion) in initial funding as part of a global response to the COVID-19 pandemic. The European Institute of Innovation and Technology (EIT) Health announced a USD 7.69 million (EUR 7 million) investment in the fight against COVID-19, which will benefit 15 countries.

Recent Developments

• In October 2020, Centivac Inc, a contract research organization, announced a strategic agreement with Thermo Fisher Scientific to license the anti-covid-19 antibodies.

Global Research Antibodies and Reagents Market Scope

The research antibodies and reagents market is segmented on the basis of product, technology, application and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

• Reagents
• Media and sera
• Stains and dyes
• Fixatives
• Buffers
• Solvents
• Enzymes
• Probes
• Other reagents
• Antibodies

Type

• Primary antibodies
• Secondary antibodies

 Form

• Monoclonal
• polyclonal
• Recombinant

 Source

• Mice
• Rabbits
• Other sources

Research area

• Oncology
• Infectious diseases
• Immunology
• Neurobiology
• Stem cells
• Other research areas

Technology

• Western Blotting
• Flow Cytometry
• Multiplex Immunosorbent Assay
• Immunoprecipitation
• Enzyme-Linked Immunosorbent Assay (ELISA)
• Immunohistochemistry
• Immunofluorescence
• Immunoprecipitation
• Other Technologies

 Application

• Proteomics
• Drug Development
• Genomics

End User

• Pharmaceutical and Biotechnologies Industries
• Academic and Research Institutions
• Contract Research Organizations

Research Antibodies and Reagents Market Regional Analysis/Insights

The research antibodies and reagents market is analysed and market size insights and trends are provided by country, product, technology, application and end user as referenced above.

The countries covered in the research antibodies and reagents market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the research antibodies and reagents market because of an increase in investments for the development of structure-based drug designs, an emphasis on research projects involving proteins, associated biomolecules, and genes.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 owing to the surge in genomics and proteomics research and development activities.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Research Antibodies and Reagents Market Share Analysis

The research antibodies and reagents market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to research antibodies and reagents market.

Some of the major players operating in the research antibodies and reagents market are:

• General Electric (U.S.)
• Merck KGaA (Germany)
• Thermo Fisher Scientific Inc. (U.S.)
• F. Hoffmann La-Roche AG (Switzerland)
• Rockland Immunochemicals Inc. (U.S.)
• Johnson & Johnson private Limited (U.S.)
• Agilent Technologies Inc. (U.S.)
• Eli Lily and Company (U.S.)
• BD (U.S.)
• Danaher (U.S.)
• PerkinElmer Inc. (U.S.)
• GenScript Biotech Corporation (U.S.)
• Lonza (Switzerland)
• Bio-Techne Corporation (U.S.)
• Bio-Rad Laboratories Inc. (U.S.)
• Teva Pharmaceutical Industries Limited (Israel)
• Santa Cruz Biotechnology Inc. (U.S.)
• BioLegend Inc. (U.S.)

SKU-10720